Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Regeneron ( (REGN) ) has shared an update.
At the J.P. Morgan Healthcare Conference on January 12, 2026, Regeneron Pharmaceuticals outlined its growth strategy centered on a robust pipeline of approximately 45 clinical programs and a portfolio of 14 internally discovered, already approved therapies. Management emphasized how the company’s integrated use of human genetics, proteomics and big data, combined with proprietary platform technologies, is intended to sustain R&D productivity and expand its leadership in key therapeutic categories, positioning Regeneron for continued growth and reinforcing its competitive standing in the biopharmaceutical sector.
The most recent analyst rating on (REGN) stock is a Buy with a $914.00 price target. To see the full list of analyst forecasts on Regeneron stock, see the REGN Stock Forecast page.
Spark’s Take on REGN Stock
According to Spark, TipRanks’ AI Analyst, REGN is a Outperform.
Regeneron’s strong financial performance and robust earnings call results are the primary drivers of its high stock score. The company demonstrates solid revenue growth and profitability, supported by a strong balance sheet and cash flow. Technical indicators show bullish momentum, though caution is advised due to overbought signals. Valuation metrics suggest the stock is fairly valued, aligning with its growth potential. Despite some operational challenges, Regeneron’s commitment to innovation and strategic investments position it well for future growth.
To see Spark’s full report on REGN stock, click here.
More about Regeneron
Regeneron Pharmaceuticals is a biotechnology company focused on discovering, developing and commercializing biologic medicines, with a portfolio spanning ophthalmology, immunology, oncology, cardiovascular and rare diseases. The company leverages a large, genetics- and proteomics-linked healthcare database and proprietary technology platforms in human antibodies, bispecifics, siRNA, gene editing and gene therapy to drive advanced drug discovery and development across roughly six core therapeutic areas.
Average Trading Volume: 997,619
Technical Sentiment Signal: Buy
Current Market Cap: $83.72B
For a thorough assessment of REGN stock, go to TipRanks’ Stock Analysis page.